

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



ROCKET PHARMACEUTICALS INC. Rank 94 of 446



The relative strengths and weaknesses of ROCKET PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ROCKET PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 42% points. The greatest weakness of ROCKET PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 159% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	364,060
Cost of Goods Sold	0
Intangible Assets	64,878
Liabilities, Current	39,169
Liabilities, Non-Current	3,683
Other Assets	93,860
Other Compr. Net Income	-196
Other Expenses	1,862
Other Liabilities	19,269
Other Net Income	453
Other Revenues	3,889
Property and Equipment	29,009
Research and Development	165,570
Selling, General and Administrative Expense	58,773

Output Variable	Value in 1000 USD
Assets	551,807
Liabilities	62,121
Expenses	226,205
Revenues	3,889
Stockholders Equity	489,686
Net Income	-221,863
Comprehensive Net Income	-221,961
Economic Capital Ratio	202%

